AI Science Tracker

Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital

1 discovery from 2023

Discoveries

AlphaFold2-Multimer screen of the 53BP1 pathway predicts a RIF1-SHLD3 interface that is confirmed in cells

Source check: Needs source check. Not independent scientific confirmation.

Finding: Sifri et al. used AlphaFold2-Multimer to predict all pairwise interactions in the 53BP1-RIF1-shieldin-CST pathway, recovered seven known interfaces and predicted a new one between the RIF1 HEAT-repeat domain and the SHLD3 eIF4E-like domain. Pulldown and cellular assays supported the model and showed the interaction is needed for shieldin recruitment, class switch recombination and PARP inhibitor sensitivity. First public version: bioRxiv 2023-01-12; journal version 2023-06-12. Abstract-level review only.

Technology: AlphaFold2-Multimer

Family AlphaFold: profile · models page

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
AlphaFold2-Multimer predicted pairwise complexes and proposed the novel RIF1-SHLD3 interface that guided the experiments.
Test and result
The predicted interface was tested by in vitro pulldown and cellular assays, per the abstract.
Limitation / still unknown
Full Methods, mutant-design details and independent replication were not assessed; the 2023-01-12 date is the bioRxiv posting (10.1101/2023.01.12.523815), version differences not compared.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/37306046 · https://doi.org/10.1101/2023.01.12.523815

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 17 Nov 2026. Review scope: abstract and bibliographic metadata (Europe PMC) only; Methods not assessed.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.